Latest News and Press Releases

Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United...

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative...

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is...

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

New York, USA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines DelveInsight | Leading Companies -...

The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...

Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...

VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for...